DexTech Medical ABXSAT:DEX -3.30%32 Current Ratio is 20.18 as of Mar. 2026, which is 18% below its 10-year median of 24.57. GuruFocus rates XSAT:DEX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, DexTech Medical AB ranks better than 92.35% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. DexTech Medical AB's current ratio for the quarter that ended in Mar. 2026 was 20.18.
DexTech Medical AB has a current ratio of 20.18. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for DexTech Medical AB's Current Ratio or its related term are showing as below:
XSAT:DEX'
s Current Ratio Range Over the Past 10 Years
Min: 0.23 Med: 24.57 Max: 196.47
Current: 20.18
During the past 13 years, DexTech Medical AB's highest Current Ratio was 196.47. The lowest was 0.23. And the median was 24.57.
XSAT:DEX's Current Ratio is ranked better than 92.35% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs XSAT:DEX: 20.18
DexTech Medical AB (XSAT:DEX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
DexTech Medical AB Current Ratio Related Terms
DexTech Medical AB Current Ratio Historical Data
* Premium members only.
The historical data trend for DexTech Medical AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:DEX vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, DexTech Medical AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexTech Medical AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where DexTech Medical AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexTech Medical AB (XSAT:DEX) has a Current Ratio of 20.18 as of Mar. 2026. This is 18% below median its historical median of 24.57. Over the past decade, DexTech Medical AB's Current Ratio has ranged from 0.23 to 196.47. According to the industry distribution chart, DexTech Medical AB ranks #108 out of 1412 companies in the Biotechnology industry, placing it in the top 7.6%.
Is DexTech Medical AB's Current Ratio too high?
DexTech Medical AB's current Current Ratio of 20.18 is 18% below median its 10-year median of 24.57. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 196.47. The Biotechnology industry median Current Ratio is 3.89. DexTech Medical AB's value of 20.18 is 418.8% above this industry median. Based on the distribution chart, DexTech Medical AB ranks #108 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DexTech Medical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #108 out of 1412 companies for Current Ratio. This places DexTech Medical AB in the top 8% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. DexTech Medical AB's value of 20.18 is 418.8% above this benchmark. Historically, DexTech Medical AB's own Current Ratio has ranged from 0.23 to 196.47 over the past decade. While the company's 10-year median is 24.57 vs. the industry median of 3.89, DexTech Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexTech Medical AB's current Current Ratio of 20.18 is 418.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current Current Ratio is 20.18, which is 18% below median its own 10-year median of 24.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Current Ratio of 20.18. The current Current Ratio is 20.18, which is 18% below median its 10-year median of 24.57 and 418.8% above the Biotechnology industry median of 3.89. DexTech Medical AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Current Ratio is 20.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
32GF Score
Get the complete analysis for XSAT:DEX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DEX has been successfully added to your 
